A 52-WEEK PHASE 3 CLINICAL TRIAL OF RESMETIROM IN 180 PATIENTS WITH WELL-COMPENSATED NASH CIRRHOSIS

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Alkhouri, Naim [2 ]
Taub, Rebecca A. [3 ]
Neff, Guy W. [4 ]
Kowdley, Kris V. [5 ]
Noureddin, Mazen [6 ]
机构：
[1] Univ Oxford, Pinaacle Res Ctr, Oxford, England
[2] Arizona Liver Hlth, Chandler, AZ USA
[3] Madrigal Pharmaceut, Conshohocken, PA USA
[4] Covenant Metab Specialists LLC, Sarasota, FL USA
[5] Liver Care Network, Seattle, WA USA
[6] Houston Methodist Hosp, Houston, TX USA
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
100
引用
收藏
页码：S90 / S92
页数：3
相关论文
共 50 条
  • [31] Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial
    Merola, J. F.
    Sidbury, R.
    Wollenberg, A.
    Chen, Z.
    Zhang, A.
    Shumel, B.
    Rossi, A. B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
  • [32] Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial
    Ketteler, Markus
    Wiecek, Andrzej
    Rosenkranz, Alexander R.
    Ose, Claudia
    Rekowski, Jan
    Lorenz, Horst
    Hellmann, Burkhard
    Karus, Michael
    Ruhmann, Michaela
    Ammer, Richard
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (04) : 982 - 991
  • [33] LONG-TERM (52-WEEK) RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS
    Kavanaugh, A.
    Mease, P. J.
    Adebajo, A. O.
    Wollenhaupt, J.
    Hu, C.
    Shah, K.
    Stevens, R. M.
    Gomez-Reino, J. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 163 - 163
  • [34] DUPILUMAB IMPROVES HISTOPATHOLOGIC ENDPOINTS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: 52-WEEK RESULTS FROM THE PHASE 3 EOE KIDS TRIAL
    Collins, Margaret H.
    Rothenberg, Marc E.
    Lerner, Diana G.
    Pesek, Robert
    Hundal, Navneet Virk
    Liu, Ruiqi
    Maloney, Jennifer
    Abdulai, Raolat M.
    Glotfelty, Lila
    Shabbir, Arsalan
    GASTROENTEROLOGY, 2024, 166 (05) : S402 - S402
  • [35] Improvement in general touch avoidance in patients with moderate-to-severe genital psoriasis treated with ixekizumab during a 52-week, randomized, phase 3 clinical trial (IXORA-Q)
    Soung, Jennifer
    Cather, Jennifer C.
    Gooderham, Melinda
    Ryan, Caitriona
    Somani, Najwa
    Feely, Meghan
    See, Kyoungah
    Burge, Russel
    Elrayes, Mohamed
    Gallo, Gaia
    Armstrong, April W.
    JEADV CLINICAL PRACTICE, 2023, 2 (02): : 282 - 292
  • [36] PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPENSATED CIRRHOSIS (CC): DATA FROM THE STELLAR-4 PHASE 3 CLINICAL TRIAL
    Younossi, Zobair M.
    Stepanova, Maria
    Nader, Fatema
    Romero-Gomez, Manuel
    Okanoue, Takeshi
    Trauner, Michael H.
    Myers, Robert P.
    Djedjos, Stephen
    Harrison, Stephen A.
    Goodman, Zachary D.
    HEPATOLOGY, 2019, 70 : 1119A - 1120A
  • [37] LONG-TERM 52-WEEK RESULTS OF PALACE 1, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS
    Adebajo, Adewale O.
    Kavanaugh, Arthur
    Mease, Philip J.
    Wollenhaupt, Juergen
    Hu, ChiaChi
    Shah, Kamal
    Stevens, Randall M.
    Gomez-Reino, Juan J.
    RHEUMATOLOGY, 2014, 53 : 141 - 141
  • [38] Long-term 52-week results of PALACE 1, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase inhibitor, in patients with psoriatic arthritis
    Adebajo, A.
    Gomez-Reino, J.
    Mease, P.
    Wollenhaupt, J.
    Hu, C. C.
    Shah, K.
    Stevens, R.
    Kavanaugh, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 12 - 12
  • [39] e-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial
    Devaraj, Anand
    Ottink, Finja
    Rennison-Jones, Christian
    Ble, Franc Comma Ois-Xavier
    Joly, Olivier
    Azim, Adnan
    Gerry, Stephen
    Harston, George
    Ostridge, Kristoffer
    George, Peter M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (09) : 1168 - 1169
  • [40] Dupilumab Improves Multiple Histopathologic Endpoints in Children With Eosinophilic Esophagitis: 52-Week Results From the Phase 3 EoE KIDS Trial
    Collins, Margaret H.
    Rothenberg, Marc E.
    Lerner, Diana
    Pesek, Robert D.
    Hundal, Navneet Virk
    Liu, Ruiqi
    Maloney, Jennifer
    Abdulai, Raolat M.
    Louisias, Margee
    Radin, Allen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S456 - S457
12345